GSK’s Clinical Development Plan For Jemperli In Rectal Cancer Draws US FDA Concerns

 
• By Sue Sutter
  
Horizon
GSK is seeking to expand dostarlimab's indication horizon with studies in rectal cancer. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers